Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report

Chidambaram, Ranganathan; Dedeepiya, Vidyasagar Devaprasad; Premkumar, Sumana; Senthilkumar, Rajappa; Rajmohan, M.; Karthick, R.; Preethy, Senthilkumar; Abraham, S

doi:10.3892/mco.2017.1333

Cited by 7 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most chemotherapeutic drugs will inhibit granulocyte production to varying degrees, further reducing immunity. Hence, breast cancer patients undergoing chemotherapy are at a high-risk of nosocomial infections (9,10). In this study, there were 36 cases among the total of 156 breast cancer patients who developed infections during chemotherapy, and the respiratory tract was the main infection site.…”

Section: Discussionmentioning

confidence: 80%

Changes in the levels of T lymphocytes and inflammatory factors in the peripheral blood of breast cancer patients during postoperative chemotherapy

Wang

Han

2020

Gland Surg

View full text Add to dashboard Cite

Background: As one of the main malignant tumors affecting women, the incidence of breast cancer increases year by year. This study aims to analyze the risk factors of infection in breast cancer patients during postoperative chemotherapy by measuring the changes in the levels of T lymphocytes and inflammatory factors in peripheral blood. Methods: The clinical data of 156 patients who underwent radical mastectomy and postoperative chemotherapy [docetaxel, epirubicin, cyclophosphamide (TEC)] in our hospital from May 2014 to April 2018 were retrospectively analyzed. According to the presence or absence of infection after chemotherapy, patients were divided into the infection group and the normal group. The risk factors of infection during chemotherapy were analyzed by univariate and multiple logistic regression analyses. Serum before surgery, and before and after chemotherapy, was collected to detect the levels of T lymphocytes and inflammatory factors.Results: A total of 36 patients developed an infection during chemotherapy, with an infection rate of 23.08%. The main infection site was the respiratory tract. The main pathogens detected were Gramnegative bacteria and Gram-positive bacteria. The results of univariate analysis showed that there were significant differences in age, diabetes mellitus, clinical TNM staging, white blood cell count (WBC), T lymphocyte subsets CD4 + /CD8 + , C-reactive protein (CRP) levels, and tumor necrosis factor-α (TNF-α) levels between the 2 groups (P<0.05). Results of logistic regression analysis showed that age ≥60 years old, diabetes mellitus, clinical TNM staging ≥ stage III, WBC <3.5×10 9 /L, CD4 + /CD8 + <1.33, TNF-α ≥70 ng/L and CRP ≥60 mg/L were all independent risk factors of postoperative infection (P<0.05). Both before and after chemotherapy, levels of CD3 + , CD3 + CD4 + and CD4 + /CD8 + cells in the infection group were significantly lower than those in the normal group, while levels of CRP, TNF-α and IL-6 were significantly higher than those in the normal group (P<0.05).Conclusions: Dynamic monitoring of changes in the levels of T lymphocytes and inflammatory factors during chemotherapy may be of clinical value for predicting the risk of infection. Implementing targeted intervention measures for these risk factors may therefore be beneficial for controlling infection.

show abstract

Section: Discussionmentioning

confidence: 80%

Changes in the levels of T lymphocytes and inflammatory factors in the peripheral blood of breast cancer patients during postoperative chemotherapy

Wang

Han

2020

Gland Surg

View full text Add to dashboard Cite

show abstract

“…Furthermore, systemic ICI treatment is accompanied by the risk of autoimmunity, in addition to adaptive and acquired resistance mechanisms, and the suppressive TME, which counteract the effects of treatment (Sutlu et al , 2009; Guillerey et al , 2016). Thus, to date, no clinical data have demonstrated significant benefits of harnessing NK cells in patients with solid tumors using available methods (Boyiadzis et al , 2017; Chidambaram et al , 2017). Nevertheless, it is possible that our novel approach to activate NK cells can be implemented in patients in vivo , to provide clinical benefits yet avoiding significant autoimmune side effects.…”

Section: Discussionmentioning

confidence: 99%

Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity

et al. 2021

View full text Add to dashboard Cite

Natural killer (NK) cells provide a powerful weapon mediating immune defense against viral infections, tumor growth, and metastatic spread. NK cells demonstrate great potential for cancer immunotherapy; they can rapidly and directly kill cancer cells in the absence of MHC-dependent antigen presentation and can initiate a robust immune response in the tumor microenvironment (TME). Nevertheless, current NK cell-based immunotherapies have several drawbacks, such as the requirement for ex vivo expansion of modified NK cells, and low transduction efficiency. Furthermore, to date, no clinical trial has demonstrated a significant benefit for NK-based therapies in patients with advanced solid tumors, mainly due to the suppressive TME. To overcome current obstacles in NK cell-based immunotherapies, we describe here a non-viral lipid nanoparticle-based delivery system that encapsulates small interfering RNAs (siRNAs) to gene silence the key intrinsic inhibitory NK cell molecules, SHP-1, Cbl-b, and c-Cbl. The nanoparticles (NPs) target NK cells in vivo, silence inhibitory checkpoint signaling molecules, and unleash NK cell activity to eliminate tumors. Thus, the novel NP-based system developed here may serve as a powerful tool for future NK cell-based therapeutic approaches.

show abstract

“…In the many years since these studies were conducted, BCG based immunotherapy has fallen out of favor in IBC. While there is one recent case of natural killer cell-based autologous immune enhancement therapy having a single patient with declining immune function [ 80 ], current treatment paradigms rely predominantly on chemo-, radio-, hormonal, and targeted therapy.…”

Section: Clinical Trials Exploring Immunotherapy In Ibcmentioning

confidence: 99%

Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy

Koch

Principe

Cataneo

et al. 2021

Cancers

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer that carries a particularly poor prognosis. Despite the efficacy of immunotherapy in other difficult to treat forms of breast cancer, progress for immunotherapy in IBC has been difficult. Though immunotherapy has been under clinical investigation in IBC since the 1970s, few approaches have shown significant therapeutic efficacy, and no immunotherapy regimens are currently used in the treatment of IBC. Here, we provide a comprehensive summary of what is known about the immune composition of IBC tumors, clinical and basic science evidence describing the role for immune checkpoints such as PD-L1 in IBC pathobiology, as well as past and present attempts to advance ICIs in the treatment of IBC.

show abstract

Cell-based immunotherapy in stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies: A case report

Cited by 7 publications

References 21 publications

Changes in the levels of T lymphocytes and inflammatory factors in the peripheral blood of breast cancer patients during postoperative chemotherapy

Changes in the levels of T lymphocytes and inflammatory factors in the peripheral blood of breast cancer patients during postoperative chemotherapy

Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity

Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy

Contact Info

Product

Resources

About